Genocea Biosciences (GNCA) PT Lowered to $15 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
FBR Capital Cuts Price Target After Genocea Biosciences (GNCA) Reports Disappointing GEN-004 Data
October 19, 2015 1:22 PM EDTFBR Capital reiterated an Outperform rating on Genocea Biosciences (NASDAQ: GNCA), and cut the price target to $17.00 (from $20.00), following top-line Phase II data for GEN-004. Although the data showed consistent reductions in the rate and density of colonization compared to placebo, neither endpoint reached statistical... More
Genocea Biosciences (GNCA) Announces GEN-004 Phase 2a Results Not Statistically Significant
October 19, 2015 7:02 AM EDTGenocea Biosciences (NASDAQ: GNCA) announced that top-line results from a Phase 2a clinical trial for GEN-004, its universal vaccine candidate against pneumococcus, showed consistent reductions versus placebo in the pre-specified endpoints of the rate and density of colonization, but that neither of the endpoints achieved statistical significance. GEN-004 was safe and well tolerated by subjects.
We are currently working with our advisors to better understand these results and to determine a next step for this program. While we did not hit statistical significance in this study, the consistent apparent effect gives us... More
